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Successful local regional therapy with topotecan ofintraperitoneally
growing human ovarian carcinoma xenografts
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Siay The therapeutic effects of intraperitoneal topotecan, a water-soluble camptothecin analogi, wer
investted in two models of human ovaran carcioma xenografted inaperitoneally into nude mice: the
IGROV-1 tumour, which originated from an untreated patient, and the A2780 tumour, selected for ristance
in vitro to cisplatin (A278ODDP). In IGROV-1 tumour-bearing mice, the optimal dose (10mgkg'1) of
topotecan, given intapertoneally every 4 days for four ocmsions markedly incrased survival time over
control mice (300 TIC'!.) and cured 4/9 mice, and such effects were not achieved by any of the clnically
available drugs tested, i.e. cisplatin, carboplatin and doxorubin delvered intraperitoneally according to their
optimal doses and In the tratment of A278ODDP tumour-bearing mice, topotecan was very
effective since, at dose klvels of 6.6 and 10mgkgI every 4 days for four occasions, 15/18 mice survived more
than 100 days, and most of them (12/15) were found to be tumour free. The high responsiveness of this
tumour to topotecan might be related to the elevated expon of the targt enzyme topoisomerase I. From
these results, intraperitoneal treatment with topotecan appears to be a promisng approach in the therapy of
refractory ovranan cancer confined to the peritoneal cavty.
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Ovarian cancer is an important cause of death in cancer
patients, and its natural history is characterised by pre-
dominant growth of the disease in the peritoneal cavity.
Thus, ovarian cancer represents a particularly good target to
exploit the pharmacological advantage (i.e. high concentra-
tion of an active agent at the tumour site) of intraperitoneal
(i.p.) administration of very potent cytotoxic agents charac-
tensed by a low therapeutic index or an unfavourable phar-
macological profile. However, local toxicity represents a
major limitation ofi.p. therapy with conventional agents (e.g.
doxorubicin, mitoxantrone). Thus, although the role of i.p.
therapy is still a matter of debate (Ozols, 1992), selection of
the appropriate drug appears to be critical for optimisation
of this approach (Markman, 1986).
Camptothecins, known as DNA topoisomerase I (topo I)
inhibitors (Liu, 1989), represent a new class of anti-tumour
agent of particular interest because in preclinical studies they
were found to be effective in the treatment of intrinsically
resistant tumours (including melanoma and colon carcinoma)
(Giovanella et al., 1989, 1991) and showed a broad spectrum
of activity (Johnson et al., 1992). Their clinical use is still
hmited by systemic toxicities, including myelosuppression
and gastrointestinal toxicity. In preclinical evaluation and in
preliminary clinical studis, these agents were found to be
devoid of local toxicity when mn rd by the i.p. and
intramuscular routes (Giovanella et al., 1991; Houghton et
al., 1992; Plaxe et al., 1993). Topotecan (10-hydroxy-9-
dimethylaminomethyl-(S)-camptothecin), CPT-l1 (7-ethyl-10-
[4-(l-piperidino)-I piperidinolcarbonyloxycamptothecin) and
9-aminocamptothecin were selected for dinical development
(Slichenmyer et al., 1993).
Human ovarian carcinomas have been successfully xeno-
grafted into nude athymic mice subcutaneously (Friedlander
et al., 1985; Kleine, 1986) and i.p. (Ward et al., 1987; Pratesi
et al., 1990a). These models closely mimic the clinical situa-
tion since tumour growth produces ascites and intraabdomi-
nal caranomatosis.
The aim of the study was to investigate the efficacy of i.p.
topotecan, a water-soluble semisynthetic camptothecin ana-
logue which does not require metabolic activation, against
two i.p. growing ovarian carcinoma xenografts, one of which
has been seected for istance to cisplatin, the most effective
drug in the clinial treatment of this tumour.
Materials an etos
Mice
Female Swiss athymic mice, 6-10 weeks old, were obtained
from Charles River Laboratory (Calco, Italy) and maintained
under standard conditions, as established by the European
Community (Directive no. 86/609/CEE).
Human tumour lines
IGROV-1 cells, from a moderately differentiated ovarian
carcinoma of an untreated patient, were grown and main-
tained by i.p. passages as alrady described (Pratesi et al.,
1990a) Tumour-bearing mice die with bulky ascites, diffuse
peritoneal carcinomatosis and often a small spleen and pale
liver. For experimental purposes, 2.5 x 10' cells per mouse
were delivered i.p.
The A278ODDP cell line was originally derived and
developed by R Ozols (National Cancer Institute, Bethesda,
MD, USA) from the A2780 human ovarian carcinoma cells
of an untreated patient (Behrens et al., 1987). After i.p.
injection of A278ODDP cells (5-10 x 10' cells per mouse),
slight ascites and diffuse abdominal carcnomatosis developed
in mice. Ascites could not be sub-pasged successflly. Solid
tumours were minced into a shlrry under sterile conditions
and susended in phosphate-buffered salin (PBS) (I g tissue/
2 ml PBS). For lne maintenanc and expermental purposes,
mice received 0.5 ml per mouse of the slurry every 20 days.
The cytological features of tumours were evaluated rou-
tinely by obsrvation of smears stained with May-Griin-
wad-GiAemsa. The human lactate dehydrogenase isoenzyme
pattern was persistently detected in tumours.
Chemotherapy studes
Topotecan was supplied by Smith-Kline Beecham Pharma-
ceuticals (Reigate, Surry, UK); cisplatin and carboplatin by
Bristol-Myers Squibb (Wallingford, CT, USA); and doxo-
rubicin by Farmitalia-Carlo Erba (Milan, Italy). Cisplatin
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was dissolved in saline and other drugs in sterile distilled
water, and all were delivered in a volume of 10 mil kg' body
weight.
Topotecan treatments were delivered i.p. every 4 days for
four occasions to tumour-bearing mice, starting 3 days after
tumour injection. This schedule was reported to be active in
a series of human subcutaneously growing tumour xenografts
(Houghton et al., 1992). For the established drugs, the max-
imum tolerated doses (i.e. less than or equal to lethal dose
killing 10% of mice) were administered in different treatment
schedules. Each experimental group included 8-9 mice, and
median survival time (MST) was calculated for dead mice
only. The death of mice before the first control mouse (or
after it with a body weight reduction of more than 30%) was
ascribed to drug toxicity. The MST of the treated mice
divided by the value of the control mice x 100 was cal-
culated and expressed as T/C%/o. Mice surviving for over 100
days were reported separately as long-term survivors (LTS).
Standard histological examination was carried out on diaph-
ragm, liver, spleen, kidneys, stomach, ovaries and uterus of
survivors.
Technical procedures for subcutaneous (s.c.) tumour xeno-
grafts have been reported (Pratesi et al., 1989). Growth of
s.c. tumours (Table II) was followed by biweekly caliper
measurement of length and width. Tumour volume (TV) was
calculated in mm3 using the formula TV = width2 x length/2
according to Geran et al. (1972). The effects achieved by the
drug treatment were expressed as TV inhibition per cent
(TVI%), which was calculated from the formula 1004T/
C x 100), where T is the mean TV of treated tumours and C
that of control tumours.
Northern blot anal vsis
Human tumours were excised from mice and cleaned free of
normal tissue. Total RNA was prepared by the lithium
chloride-guanidine monothiocianate method (Cathala et al.,
1983) from frozen solid tumour tissue. Northern blot analysis
was performed as already described (Pratesi et al., 1990b).
Briefly, total RNA (20ptg) was fractionated on a formal-
dehyde-containing 1% agarose gel and transferred to a
Hybond-N filter. Hybridisations were carried out for 20 h at
42'C with denaturated random primed topo I or -y-actin
probes (Juan et al., 1988; Miwa and Kamada, 1990). The
final wash of the filter was performed at 55°C in 0.5 x SSPE
(3.6 M sodium chloride, 0.2 M sodium phosphate pH 7.7,
0.02 M disodium EDTA), and autoradiography was carried
out at - 70C on Amersham MP film. Topo I gene expres-
sion was quantified using a Phosphorlmager (Molecular
Dynamics, Sunnyvale, CA, USA) by dividing the radio-
activity of the transcnpt by that of the -tactin gene.
Resuts
The effect of i.p. topotecan on survival time of IGROV-1
tumour-bearing mice is shown in Figure 1. Topotecan show-
ed a dose-dependent effect, since 10 mg kg-' was the optimal
dose when given every 4 days for four occasions, and 15 mg
kg- I was toxic (five of nine mice died before the first control
mouse). Table I compares the efficacy against the i.p. grow-
ing IGROV-1 tumour of anti-tumour drugs employed in
clinical therapy of ovarian carcinoma. A direct comparison
of drug efficacy was carried out between doxorubicin and
topotecan and a statistically significant difference in mice
survival time was achieved (doxorubicin vs topotecan 10 mg
kg-', P<0.001 by two-sided Mann-Whitney rank test}. The
results reported for the other drugs were obtained from
different experiments in which each drug was delivered i.p. at
its optimal dose according to different treatment schedules.
Topotecan at its optimal dose was the most effective agent in
the treatment of the IGROV-1 tumour, in terms of an in-
crease in survival time as well as the number of long-term
survivors. When sacrificed at the end of the experiment, mice
treated with topotecan presented few tumour nodules in the
peritoneal cavity and no ascites.
Figure 2 presents the effects of topotecan and cisplatin on
the survival time of A278ODDP tumour-bearing mice. The
drugs were delivered according to the same treatment
schedule (every 4 days for four occasions). As expected,
cisplatin produced only a marginal increase in mice MST
(TIC'/o = 162) without inducing long-term survival. In con-
trast, all mice but one survived over 100 days in the group
treated with the optimal dose of topotecan (10 mg kg'- ), and
all but two in the group treated with the lower dose (P<
0.001 for both topotecan doses vs cisplatin by two-sided
Mann- Whitney rank test). At necropsy, 3 of the 15 sur-
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Fugwe 1 Activity of topotecan against IGROV-1 human ovarian
carcinoma. Female Swiss nulnu mice, inoculated i.p. with
2.5 x 106 cells per mouse, were treated i.p. at days 3, 7, 11 and 15
with topotecan, 6.6 (A), 10 (O) and 15 (0) mg kg-'. Untreated
controls (0). Each group consisted of nine mice.
Table I Efficacy of local regional treatment with anti-tumour drugs on the IGROV-I
tumour xenograft growing i.p.
Dose Days of No. of deathsl
Drug (mgkg-' treatment no. of mice T/C% LTS
Topotecan 6.6 3, 7, 11, 15 0/9 260 0/9
10 3, 7, 11, 15 0/9 300 4/9
15 3, 7, 11, 15 519 53 1/9
Doxorubicin 5 3, 7, 11, 15 1!/9 233 0,l9
7.5 8. 15, 22 0/16 205-228b 0116
Cisplatin 4 3, 7, 11 0/19 185-200b 2, 19
4 7, 11. 15 0!9 140 1'9
6 8, 15, 22 5/55 170-250c 6 55
Carboplatin 60 7, 11, 15 1/9 95 1'9
'Calculated on dead mice only. bResults from two experiments. CRange of values in six
experiments.vivors presented few tumour nodules in the peritoneal cavity.
In the other 12 surviving mice, histological examination of
abdominal organs (spkeen, liver, diaphragm, stomach,
kidneys, ovaries and uterus) showed no evidence of
disease.
In order to demonstrate the drug resistance of the
A27809DDP tumour line, cisplatin activity was compared in
s.c. growing A2780 and A278ODDP tumours, because the
parent cell line only occasionally grows in the ascitic form
after i.p. transplantation and could not be established as an
i.p. tumour model. Although the two tumours had a similar
Izu -
. '
cn
(I)
Fr'P
hulma
i.p. 'A
methc
4mgl
treato
T
100o
80 -
60 -
40 -
20 -
0-
a bopd hb= bp ~ inLp. puvgwwin cmm men-P b
G Praesi et a
527
growth rate in the nude mouse (doublng time around 4
days), the A278ODDP tumour was resistant to intravenous
treatment with cisplatin (days 3, 10 and 17), which, on the
contrary, inhibited tumour growth of the parent A2780
tumour even when delivered to advanced tumours (days 14,
21 and 28) (Table II).
Figure 3 shows the levels of topoisomerase I expression in
IGROV-1 and A2780 parent tumour lines and their cisplatin-
resistant variant. The A278ODDP tumour line, which was
highly sensitive to topotecan, had the highest enzyme level.
Local regional treatment with topotecan of two human ovar-
i carcinomas growing i.p. in nude mice resulted in a
marked increase in survival time and a high number of
survivors, most of which had no evidence of tumour in the
m 4 Q A < abdominal cavity even when inspected histologically. Topo-
tecan was the most active compound the IGROV-l
tumour compared with established anti-tumour drugs em-
ployed in the clinical therapy of ovarian carcinoma. The
anti-tumour activity of local regional topotecan treatment
could not be assessed in the IGROV-DDP tumour line,
4* (yO because these cells in the nude mice do not grow as ascites
but only subcutaneously. The results in IGROV-1 tumour
(31;) support the opportunity of clinical phase H trials with i.p.
pp topotecan in patients with ovarian carcinoma. Reduction in
ascites has been reported in a phase I trial of i.p. topotecan
(Plaxe et al., 1993).
20 40 60 80 100 120 Interestingly, topotecan was impressively active against the
Days A2780 tumour made resistant to isplatin. As already sug-
e 2 Activity of topotecan and cisplatin against A278ODDP gested by a phase I clinical study (Rowinsky et al., 1992), this
n ovaran carcnoma. Female Swiss nu/nu mice inoculated finding indicates that the compound should be evaluated in
with 0.5 ml per mouse of a slurry (see Materials and clinical trials for r current ovarian carcinoma refractory to
ids) were treated i.p. at days 3, 7, 11 and 15 with cisplatin, cisplatin. Northen blot analysis indicated that the A278ODDP
kg-' (0), or topotecan, 6.6 (A) or 10 (O) mg kg-'. Un- tumour line has a very high level of topo I expression. It is
d controls (0). Each group consisted of nine mice. therefore likely that the impressive anti-tumour efficacy of
topotecan against this tumour was related to the level of
1 2 3 4 expression ofthe primary target ofthe drug (Liu, 1989). This
2 interpretation is supported by the fact that in camptothecin-
resistant cell lines a reduction in the amount of DNA topo I
>v* : - (Kanzawa et al., 1990) as weH as a qualitative alteration of
the enzyme thanizawa and Pommier, 1992) have been report-
ed. Whether this cisplatin-resistant tumour exhibits a true
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the s.c.
Tumour
A2780
A2780D
aMean tl
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collateral sensitivity to topotecan compared with the parent
A2780 tumour remains to be determined in the s.c. growing
tumours. In fact, a comparable local regional treatment of
parent and cisplatin-resistant tumours is not possible, since
the former grew poorly after i.p. inoculation in the nude
0.027 0.033 0.083 0.150 mice. Evidence of this hypothesis has been reported in a
human cisplatin-resistant bladder cancer cell line (Kotoh et
3 Northern blot analysis oftopo I expression in cisplatin- al., 1994). An increased topo I expression in cisplatin-
ve and -resistant tumour lines: lane 1, IGROV-1; 2, resistant cells is not surpring, sice the enzyme may be
IV-DDP; 3, A2780; 4, A2780-DDP. Norern blot was involved in repairing DNA damage (Slichenmyer et al.,
med on agarose-formaldehyde (1%) gel electrophoresis of 1993). However, an overexpression of topo I following
RNA (20gg). RNA fragments were transferred to a development of resistance to cisplatin could not be regrded
id-N filter and were hybridised with PP-labelled probes,
a random primer kit. A Phosphorimager was used to aGeneral pemo n, and it was nt fo in th
iine the levels of topo I gene expression, which was nor- IGROV-DDP tumour (Figudre 3). Relevant to this poit Is
d for RNA loading by dividing the absorbance of the the obseration that there was no differn in dian topo I
ripts by that of the -tactin. The numbers reported in the activity in untreated and platimum-treated patients (van der
refer to topoisomerase I expression relative to -tactin Zee et al., 1991). Taken together, these observations support
sion. the interest in the use of topo I inhibitors for platinum-
pretreated ovarian cancer.
An additional interest for the local regional use ofcampto- ICisplatin (6mgkg-' per treatment, i.v) efficacy agist thcins derives from their behaviour in aqueous solutions
human ovarian A2780 xenograft and its cisplatin-resistant derbergvesa!., thesehagen areown tolunderg
variant (Underberg et al., 1990).Tlese agents are known to undergo
a pH-dependent interconversion between active lactone and
TreatMent inactive carboxylate forms. It is evident that i.p. administra-
line Days Tm ohone (mm3) TVI%b tion allows a more rapid access than systemic therapy of the
14, 21, 28 500 65 active drug form to the cellular target, thereby preventing the
iDP 3, 10, 17 50 30 expected interconversion at the plasma level.
umour volume at the first day of treatment. 'Tumour volume In summary, i.p. treatment with topotecan appears to be
on per cent I week after the last treatment. feasible since the drug is well tolerated, with no evidene of
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local tissue damage (i.e. typical local toxicity of most
cytotoxic agents). Moreover, from this preclinical study, i.p.
topotecan seems to be a very promising approach for future
attempts to optimise treatment of ovarian cancer confined to
the peritoneal cavity, as a consolidation therapy after a
cisplatin-based treatment or as a second-line therapy for
refractory disease.
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